Franklin Resources Inc. Purchases 125,519 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Franklin Resources Inc. lifted its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 3.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,137,567 shares of the company’s stock after purchasing an additional 125,519 shares during the quarter. Franklin Resources Inc. owned about 6.06% of EyePoint Pharmaceuticals worth $30,825,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Wellington Management Group LLP raised its position in shares of EyePoint Pharmaceuticals by 3.2% during the 4th quarter. Wellington Management Group LLP now owns 177,316 shares of the company’s stock valued at $1,321,000 after buying an additional 5,552 shares in the last quarter. Schroder Investment Management Group increased its stake in EyePoint Pharmaceuticals by 118.1% in the fourth quarter. Schroder Investment Management Group now owns 270,336 shares of the company’s stock valued at $1,898,000 after acquiring an additional 146,403 shares during the last quarter. JPMorgan Chase & Co. raised its position in EyePoint Pharmaceuticals by 6.4% during the fourth quarter. JPMorgan Chase & Co. now owns 395,444 shares of the company’s stock valued at $2,946,000 after purchasing an additional 23,686 shares in the last quarter. Corebridge Financial Inc. lifted its stake in EyePoint Pharmaceuticals by 21.6% during the fourth quarter. Corebridge Financial Inc. now owns 32,499 shares of the company’s stock worth $242,000 after purchasing an additional 5,765 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of EyePoint Pharmaceuticals by 24.8% in the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company’s stock worth $28,334,000 after purchasing an additional 755,045 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Stock Down 7.6 %

Shares of EYPT stock opened at $4.61 on Friday. The stock has a fifty day moving average of $6.47 and a 200 day moving average of $8.10. The firm has a market capitalization of $316.84 million, a price-to-earnings ratio of -2.31 and a beta of 1.41. EyePoint Pharmaceuticals, Inc. has a 52 week low of $4.51 and a 52 week high of $23.65.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The firm had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million. Equities research analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on EYPT. StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. Chardan Capital reiterated a “buy” rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Citigroup started coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $33.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.